Skip to main content

Alzheimer's Disease

Volume 448: debated on Tuesday 4 July 2006

To ask the Secretary of State for Health what (a) meetings were held and (b) correspondence was exchanged between (i) Ministers and (ii) officials in her Department and the National Institute for Health and Clinical Excellence (NICE) regarding the NICE appraisal of Donepezil, Rivastigmine, Galantamine and Memantine for the treatment of Alzheimer's disease. (81667)

[holding answer 3 July 2006]: Ministers received a brief oral update on this appraisal from National Institute for Health and Clinical Excellence (NICE) officials on 7 June 2006. The progress of this appraisal also has been discussed with Ministers within the context of NICE's wider work programme at meetings on 2 March 2005 with NICE's chief executive and on 9 June 2005 with NICE's chief executive and chair.

Departmental officials have had no meetings with NICE specifically to discuss this appraisal, but the progress of the appraisal has been discussed as part of the regular communications between NICE and the Department.

The Department responded in writing to NICE's two consultation documents as part of this appraisal. Copies of the Department's responses are available in the Library.